In a recent article in the New Scientist clinical trials supplement Dr Jorg Taubel, Scientific Lead at Richmond Research Institute, highlights the importance of reducing the risk to patients in phase I clinical trials.
As medicines become more personalised it will become necessary to conduct phase I trials directly with the target population. This must be approached with caution and improvements to phase I to trial design must be made before transferring the well-established healthy volunteer tool kit to patients who will often have complicated medical histories.
The drug action must be fully understood before conducting first in human trials.
Read the article in full - https://www.richmondresearchinstitute.org/news/dr-jorg-taubel-stresses-w...
To learn more about Richmond Research Institute visit www.richmondresearchinstitute.org